Mi az ára Pascal Biosciences Inc. (PSCBF)

Pascal Biosciences Inc. (PSCBF) ára $0.1

Mi a Pascal Biosciences Inc. (PSCBF piaci tőkésítése)

Pascal Biosciences Inc. piaci tőkésítése (PSCBF) $1.31M

Pascal Biosciences Inc. (PSCBF) P/B mutató

Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.

Év	P/B arány	Változtassa meg
2026 (TTM)	2.64	127.72%
2023	1.16	-181.08%
2022	-1.43	7,479.37%
2021	-0.02	6,200.00%
2020	0.00	0.00%
2019	0.00	0.00%

Év

P/B arány

Változtassa meg

2026 (TTM)

2.64

127.72%

2023

1.16

-181.08%

2022

-1.43

7,479.37%

2021

-0.02

6,200.00%

2020

0.00

0.00%

2019

0.00

0.00%

Vállalat	P/B arány	P/B arány különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	137.04%	US
Argenx SE ARGX.US	6.3483	140.33%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	37.57%	BE

Vállalat

P/B arány

P/B arány különbség

Ország